Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis

Osimertinib—the third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)—has been widely used as an first-line treatment for patients with metastatic EGFR-mutant non-small cell lung cancer (NSCLC).